Jeffrey R. Weidner
Merck & Co.
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jeffrey R. Weidner.
Gastroenterology | 1996
Irwin I. Singer; Douglas W. Kawka; S Scott; Jeffrey R. Weidner; Richard A. Mumford; Te Riehl; Wf Stenson
BACKGROUND & AIMS Inducible nitric oxide synthase (iNOS) is generated in several cell types by treatment with lipopolysaccharides or cytokines. Earlier studies suggested that ulcerative colitis is associated with increased NO produced by iNOS; however, the cellular source of the NO synthesis was not identified. A possible mechanism of NO-induced cellular damage is through its interaction with superoxide to produce peroxynitrite, which reacts with tyrosine to form nitrotyrosine in cellular proteins. METHODS Using immunoperoxidase microscopy with a new monospecific human iNOS antibody (NO-53), the cellular distribution of iNOS and nitrotyrosine was examined using human colonic mucosa from normal bowel, ulcerative colitis, Crohns disease, and diverticulitis. RESULTS Intense focal iNOS labeling was localized to the inflamed colonic epithelium in ulcerative colitis, Crohns disease, and diverticulitis but was not detectable in the uninflamed epithelium. Nitrotyrosine labeling was also observed in the inflamed colonic epithelium and was associated with nearby iNOS staining; nitrotyrosine was undetectable in normal mucosal epithelium. iNOS and nitrotyrosine were also detected in lamina propria mononuclear cells and neutrophils. CONCLUSIONS These findings suggest that iNOS is induced in the inflamed human colonic epithelium and is associated with the formation of peroxynitrite and the nitration of cellular proteins.
Journal of Clinical Investigation | 1995
Irwin I. Singer; Douglas W. Kawka; Ellen K. Bayne; Susan Donatelli; Jeffrey R. Weidner; Hollis R. Williams; Julia M. Ayala; Richard A. Mumford; Michael W. Lark; Tibor T. Glant
The destruction of articular cartilage in immune inflammatory arthritic disease involves the proteolytic degradation of its extracellular matrix. The role of activated matrix metalloproteinases (MMPs) in the chondrodestructive process was studied by identifying a selective cleavage product of aggrecan in murine arthritis models initiated by immunization with either type II collagen or proteoglycan. We conducted semiquantitative immunocytochemical studies of VDIPEN341 using a monospecific polyclonal antibody requiring the free COOH group of the COOH-terminal Asn for epitope detection. This antibody recognizes the aggrecan G1 domain fragment generated by MMP [i.e., stromelysin (SLN) or gelatinase A] cleavage of aggrecan between Asn341-Phe342 but does not recognize intact aggrecan. VDIPEN was undetectable in normal mouse cartilage but was observed in the articular cartilage (AC) of mice with collagen-induced arthritis 10 d after immunization, without histological damage and clinical symptoms. This aggrecan neoepitope was colocalized with high levels of glycosaminoglycans (GAGs) in pericellular matrices of AC chondrocytes but was not seen at the articular surface at this early time. Digestion of normal (VDIPEN negative) mouse paw cryosections with SLN also produced heavy pericellular VDIPEN labeling. Computer-based image analysis showed that the amount of VDIPEN expression increased dramatically by 20 d (70% of the SLN maximum) and was correlated with GAG depletion. Both infiltration of inflammatory cells into the synovial cavity and early AC erosion were also very prominent at this time. Analysis of adjacent sections showed that both induction of VDIPEN and GAG depletion were strikingly codistributed within sites of articular cartilage damage. Similar results occurred in proteoglycan-induced arthritis, a more progressive and chronic model of inflammatory arthritis. These studies demonstrate for the first time the MMP-dependent catabolism of aggrecan at sites of chondrodestruction during inflammatory arthritis.
Journal of Biological Chemistry | 1996
Jimmy R. Calaycay; Theresa M. Kelly; Karen L. MacNaul; Ermenegilda McCauley; Hongbo Qi; Stephan K. Grant; Patrick R. Griffin; Tracey Klatt; S. M. Raju; Andreas K. Nussler; Shrenik K. Shah; Jeffrey R. Weidner; Hollis R. Williams; Gloria C. Wolfe; David A. Geller; Timothy R. Billiar; Malcolm Maccoss; Richard A. Mumford; Michael J. Tocci; John A. Schmidt; Kenny K. Wong; Nancy I. Hutchinson
Recombinant human inducible nitric-oxide synthase (rH-iNOS) was expressed in the baculovirus system and purified by a novel immunoaffinity column. rH-iNOS and its native counterpart from cytokine-stimulated primary hepatocytes exhibited similar molecular mass of 130 kDa on SDS-polyacrylamide gel electrophoresis, recognition by antipeptide antibodies, specific activities, and IC50 values for inhibitors. The active dimeric form exhibited a specific activity range of 114-260 nmol/min/mg at 37°C and contained 1.15 ± 0.04 mol of calmodulin/monomer. The enzyme exhibited a Soret λmax at 396 nm with a shoulder at 460 nm and contained 0.28-0.64 mol of heme/monomer. Dithionite reduction under CO yielded an absorbance maximum at 446 nm, indicating a P450-type heme. Imidazole induced a type II difference spectrum, reversible by L-Arg. 2-Amino-5,6-dihydro-4H-1,3-thiazine (ADT) was competitive versus L-Arg (Ki = 22.6 ± 1.9 nM), reversed the type II difference spectrum induced by imidazole (Kd = 17.7 nM), and altered the CO-ferrous absorbance of rH-iNOS. L-Arg did not perturb the CO-ferrous adduct directly, but it partially reversed the ADT-induced absorbance shift, indicating that both bind similarly to the protein but interact differently with the heme.
Nature | 1992
Nancy A. Thornberry; Herbert G. Bull; Jimmy R. Calaycay; Kevin T. Chapman; Andrew D. Howard; Matthew Kostura; Douglas K. Miller; Susan Molineaux; Jeffrey R. Weidner; John Aunins; Keith O. Elliston; Julia M. Ayala; Francesca J. Casano; Jayne Chin; Gloria J.-F. Ding; Linda A. Egger; Erin P. Gaffney; Guadalupe A. Limjuco; Oksana C. Palyha; S. M. Raju; Anna Rolando; J. Paul Salley; Ting-Ting Yamin; Terry D. Lee; John E. Shively; Malcolm MacCross; Richard A. Mumford; John A. Schmidt; Michael J. Tocci
Journal of Experimental Medicine | 1996
Iain B. McInnes; Bernard P. Leung; Max Field; Xiao-Qing Wei; Fang-Ping Huang; Roger D. Sturrock; Andrew Wg G Kinninmonth; Jeffrey R. Weidner; Richard A. Mumford; Fooyew Liew
Journal of Immunology | 1991
Andrew D. Howard; M J Kostura; Nancy A. Thornberry; G J Ding; Guadalupe A. Limjuco; Jeffrey R. Weidner; J P Salley; K A Hogquist; D D Chaplin; Richard A. Mumford
Journal of Immunology | 1998
Judy E. Fenyk-Melody; Augusta E. Garrison; Steven R. Brunnert; Jeffrey R. Weidner; Frank Shen; Beverly A. Shelton; John S. Mudgett
Journal of Biological Chemistry | 1995
Michael W. Lark; John T. Gordy; Jeffrey R. Weidner; Julia M. Ayala; James H. Kimura; Hollis R. Williams; Richard A. Mumford; Carl R. Flannery; Steven S. Carlson; Mineo Iwata; John D. Sandy
Journal of Biological Chemistry | 1994
T J Sewell; E Lam; M M Martin; John D. Leszyk; Jeffrey R. Weidner; Jimmy R. Calaycay; Patrick R. Griffin; Hollis R. Williams; S Hung; J Cryan
Osteoarthritis and Cartilage | 1997
Irwin I. Singer; Sol Scott; Douglas W. Kawka; Ellen K. Bayne; Jeffrey R. Weidner; Hollis R. Williams; Richard A. Mumford; Michael W. Lark; Joseph McDonnell; Amy J. Christen; Vernon L. Moore; John S. Mudgett; Denise M. Visco